Senior Research Associate/ Biosafety Manager

Annabelle Mouchotte


“Embrace ideas from an innovative company, where patient is put in the first page to deliver the best medicine.”

Your role at Institut Roche and brief presentation of your professional background:

I joined Institut Roche in 2016 as Research Associate. I’m responsible of in vitro and ex vivo activities on a oncology preclinical research and development project. My work as always been related to oncology. I started my career in the academic field working in cancer metabolism then when I joined Institut Roche in 2016 where I shifted to immuno-oncology.

My Focus at Institut Roche:

I am part of a team working on the development of a new modality of radio-immunotherapy based on 212 Pb (Lead-212) in collaboration with OranoMed company.

  1. Chiche, J., et al. (2019). “GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors.” Cell Metab. 2019 Jun 4;29(6):1243-1257.
  2. Chiche, J., et al. (2015). “GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin’s B lymphomas via NF­κB dependent induction of HIF‐1α.” Leukemia. 2015 May;29(5):1163-76.
More publications